Abstract
Objectives
Patients with psoriasis may have a higher risk of developing chronic kidney (CKD) and end-stage renal disease (ESRD) compared with general population. This systematic review and meta-analysis aimed to comprehensively investigate this association by reviewing all available evidence.
Methods
A systematic review was performed using MEDLINE and EMBASE database from inception to January 2018 to identify all cohort studies that compared the risk of incident CKD and/or ESRD in patients with psoriasis versus individuals without psoriasis. Pooled risk ratio and 95% confidence interval were calculated using random-effect, generic inverse variance method.
Results
A total of four retrospective cohort studies with 199,808 patients with psoriasis were included. The risk of incident CKD and ESRD was significantly increased among patients with psoriasis with the pooled risk ratio of 1.34 (95% CI, 1.14–1.57) and 1.29 (95% CI, 1.05–1.60), respectively.
Conclusion
A significantly increased risk of incident CKD and ESRD among patients with psoriasis compared with individuals without psoriasis was demonstrated in this study.
Similar content being viewed by others
References
Naldi L (2004) Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 3:121–128
Gisondi P (2017) High prevalence of alcohol use disorders in patients with inflammatory skin diseases applies to both psoriasis and eczema. Br J Dermatol 177:606–607
Duffy DL, Spelman LS, Martin NG (1993) Psoriasis in Australian twins. J Am Acad Dermatol 29:428–434
Correia B, Torres T (2015) Obesity: a key component of psoriasis. Acta Biomed 86:121–129
Naldi L, Mercuri SR (2009) Smoking and psoriasis: from epidemiology to pathomechanism. J Invest Dermatol 129:2741–2743
Kokpol C, Aekplakorn W, Rajatanavin N (2014) Prevalence and characteristics of metabolic syndrome in South-East Asian psoriatic patients: a case-control study. J Dermatol 41:898–902
Ungprasert P, Sanguankeo A, Upala S et al (2014) Psoriasis and venous thromboembolism: a systematic review and meta-analysis. QJM 107:793–797
Ungprasert P, Srivali N, Kittanamongkolchai W (2016) Psoriasis and risk of incident atrial fibrillation: a systematic review and meta-analysis. Indian J Dermatol Venereol Leprol 82:489–497
Bissonnette R, Kerdel F, Naldi L et al (2017) Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis. J Drugs Dermatol 16:1002–1013
Libby P (2002) Inflammation in atherosclerosis. Nature 420:868–874
Maradit-Kremers H, Nicola PJ, Crowson CS et al (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52:722–732
Wan J, Wang S, Haynes K et al (2013) Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ 347:f5961
Chiu HY, Huang HL, Li CH et al (2015) Increased risk of glomerulonephritis and chronic kidney disease in relation to severity of psoriasis, concomitant medication, and comorbidity: a nation-wide population-based cohort study. Br J Dermatol 173:146–154
Parisi R, Rutter MK, Lunt M et al (2015) Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink. J Invest Dermatol 135:2189–2197
Yu S, Tu HP, Yu CL et al (2017) Is psoriasis an independent risk factor of renal disease? A nationwide retrospective cohort study from 1996 to 2010. Dermatol Sin 35:78–84
Stang A (2010) Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trial 7:177–188
Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
Ozyilmaz A, de Jong PE, Gansevoort RT (2012) Screening for chronic kidney disease can be of help to prevent atherosclerotic end-organ damage. Nephrol Dial Transplant 27:4046–4052
Shahwan KT, Kimball AB (2015) Psoriasis and cardiovascular disease. Med Clin N Am 99:1227–1242
Ogawa E, Sato Y, Minagawa A et al (2017) Pathogenesis of psoriasis and development of treatment. J Dermatol (epub ahead of pirnt)
Turner JE, Paust HJ, Steinmetz OM et al (2010) The Th17 immune response in renal inflammation. Kidney Int 77:1070e5
Kitching AR, Holdsworth SR (2011) The emergence of TH17 cells as effectors of renal injury. J Am Soc Nephrol 22:235e8
Imai H, Kodama T, Ishino T et al (1995) IgA nephropathy associated with hyper IgAnemia, psoriasis or pustulosis and ossification. Clin Nephrol 44:64–68
Zadrazil J, Tichy T, Horak P et al (2006) IgA nephropathy associated with psoriasis vulgaris: a contribution to the entity of ‘psoriatic nephropathy’. J Nephrol 19:382–386
Kluger N, Du-Thanh A, Bessis D et al (2015) Psoriasis-associated IgA nephropathy under infliximab therapy. Int J Dermatol 54:e79–e80
Kaji T, Tsukada Y, Shimada A et al (1994) Membranous nephropathy associated with psoriasis vulgaris. Clin Nephrol 42:63–64
Author information
Authors and Affiliations
Contributions
All authors had access to the data and a role in writing the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
We do not have any financial or non-financial potential conflicts of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
11255_2018_1868_MOESM2_ESM.docx
Supplementary material 2: The report of this systematic review and meta-analysis is in full compliance with the guideline meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group which is provided as supplementary data 2. (DOCX 17 kb)
Rights and permissions
About this article
Cite this article
Ungprasert, P., Raksasuk, S. Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. Int Urol Nephrol 50, 1277–1283 (2018). https://doi.org/10.1007/s11255-018-1868-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-018-1868-z